PRAX

Company Overview — What Does Praxis Precision Medicines, Inc. Do?

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. Praxis Precision Medicines, Inc. (PRAX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Marcio Souza and employs approximately 110 people. With a market capitalization of $8.9B, PRAX is one of the notable companies in the Healthcare sector.

Praxis Precision Medicines, Inc. (PRAX) Stock Rating — Reduce (April 2026)

As of April 2026, Praxis Precision Medicines, Inc. receives a Reduce rating with a composite score of 36.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PRAX ranks #2,597 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Praxis Precision Medicines, Inc. ranks #338 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PRAX Stock Price and 52-Week Range

Praxis Precision Medicines, Inc. (PRAX) currently trades at $316.14. The stock lost $4.10 (1.3%) in the most recent trading session. The 52-week high for PRAX is $356.00, which means the stock is currently trading -11.2% from its annual peak. The 52-week low is $26.70, putting the stock 1084.0% above its annual trough. Recent trading volume was 254K shares, suggesting relatively thin trading activity.

Is PRAX Overvalued or Undervalued? — Valuation Analysis

Praxis Precision Medicines, Inc. (PRAX) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.73x, versus the sector average of 2.75x. The price-to-sales ratio is 28283.35x, compared to 1.66x for the average Healthcare stock.

At current multiples, Praxis Precision Medicines, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Praxis Precision Medicines, Inc. Profitability — ROE, Margins, and Quality Score

Praxis Precision Medicines, Inc. (PRAX) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -30.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -28.4% versus the sector average of -33.1%.

The operating margin is -18819.5% (sector: -66.1%). Net profit margin stands at -17188.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PRAX Debt, Balance Sheet, and Financial Health

Praxis Precision Medicines, Inc. has a debt-to-equity ratio of 7.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.22x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $150M.

PRAX has a beta of 0.75, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Praxis Precision Medicines, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Praxis Precision Medicines, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Praxis Precision Medicines, Inc. reported revenue of $302,000 and earnings per share (EPS) of $-13.48. Net income for the quarter was $-266M. Operating income came in at $-286M.

In FY 2025, Praxis Precision Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-13.48. Net income for the quarter was $-303M. Operating income came in at $-326M.

In Q3 2025, Praxis Precision Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.36. Net income for the quarter was $-74M. Operating income came in at $-78M.

In Q2 2025, Praxis Precision Medicines, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.31. Net income for the quarter was $-71M. Operating income came in at $-76M.

Over the past 8 quarters, Praxis Precision Medicines, Inc. has experienced revenue contraction from $357,000 to $302,000. Investors analyzing PRAX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PRAX Dividend Yield and Income Analysis

Praxis Precision Medicines, Inc. (PRAX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PRAX Momentum and Technical Analysis Profile

Praxis Precision Medicines, Inc. (PRAX) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PRAX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Praxis Precision Medicines, Inc. (PRAX) ranks #338 out of 838 stocks based on the Blank Capital composite score. This places PRAX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PRAX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PRAX vs S&P 500 (SPY) comparison to assess how Praxis Precision Medicines, Inc. stacks up against the broader market across all factor dimensions.

PRAX Next Earnings Date

No upcoming earnings date has been announced for Praxis Precision Medicines, Inc. (PRAX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PRAX? — Investment Thesis Summary

The quantitative profile for Praxis Precision Medicines, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 30/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers. High volatility (stability score 31/100) increases portfolio risk.

In summary, Praxis Precision Medicines, Inc. (PRAX) earns a Reduce rating with a composite score of 36.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PRAX stock.

Related Resources for PRAX Investors

Explore more research and tools: PRAX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PRAX head-to-head with peers: PRAX vs AZN, PRAX vs SLGL, PRAX vs VMD.